Somerset, NJ, April 1, 2020 – Legend Biotech Corporation (Legend), a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced today that it has raised $150.5 million in Series A financing. Proceeds from the financing will be used to advance the research and development […]

Somerset, NJ (March 9, 2020): — Legend Biotech Corporation today announced that it has confidentially submitted a draft registration statement on Form F-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of American depositary shares, representing its ordinary shares. The number of American depositary shares to be offered […]

Piscataway, NJ, January 28, 2020 – Legend Biotech announced that, according to the terms and conditions of an agreement with Janssen Biotech, Inc. (Janssen), the fourth milestone payment has been achieved relating to the U.S. clinical development of the B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, LCAR-B38M (JNJ-68284528 (JNJ-4528)). “We are pleased […]

SOMERSET, N.J.— (BUSINESS WIRE)—August 30, 2021—Legend Biotech Corporation (NASDAQ: LEGN), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will participate in the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on Friday, September 10. Ying Huang, Chief Executive Officer and Chief Financial Officer, […]

SOMERSET, N.J.—(BUSINESS WIRE)—August 23, 2021—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today reported its 2021 second quarter unaudited financial results. “We have made exciting progress in advancing our first investigational CAR-T therapy cilta-cel in the […]